Launched in April 2022, Cellistic specializes in process development and manufacture of cell therapies based on human induced pluripotent stem cell (iPSC) technology. The company’s focus and expertise in iPSC generation and differentiation protocol development makes it well-positioned to partner with innovative cell therapy developers to establish novel advanced therapies. With more than a decade of scientific and technical knowledge transfer from sister company Ncardia, Cellistic is uniquely experienced in designing and optimizing manufacturing procedures for iPSCs that deliver quality products at scale. For more information, visit www.cellistic.com.
| Website | https://www.cellistic.com/ |
| Revenue | $702.1 million |
| Employees | 84 (66 on RocketReach) |
| Industry | Biotechnology Research |
| Keywords | Cell Therapy Manufacturing, Process Development, Stem Cell Therapies, Cellular Therapies, Regenerative Medicine, Cell Therapy, Pluripotent Stem Cells, Biopharmaceutical Manufacturing, Pharmaceutical Manufacturing, Bioprocessing, Cell Culture, Stem Cell Research, Cell Manufacturing, Drug Development, Biotechnology, Pharmaceutical |
| Competitors | Novartis, Regeneron, Vertex Pharmaceuticals, Beam Therapeutics, Intellia Therapeutics, Inc., CRISPR Therapeutics, bluebird bio, Editas Medicine, Sangamo Therapeutics, Inc., Avidity Biosciences, Inc. +43 more (view full list) |
Looking for a particular Cellistic employee's phone or email?
The Cellistic annual revenue was $702.1 million in 2026.
Gustavo Mahler is the CEO of Cellistic.
66 people are employed at Cellistic.